Obesity is a key risk factor for CRC development, and accumulating evidence indicates that increased secretion of adipokines, including Visfatin, under obese conditions contributes to the development of resistance in CRC to various therapeutic methods. This evidence concerns the gene NAMPT and obesity due to melanocortin 4 receptor deficiency.